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neutrophil erythrophagocytosis) allowing the identification of this
cytogenetic abnormality with high sensitivity (70%) and specificity
(85.7%). Suspected ider(20q) by morphology should therefore sup-
port targeted FISH tests in case of non-informative karyotype. This
combined approach will allow a better estimation of the prevalence
of this underdiagnozed entity.
Conclusion.— The overall survival and progression free survival did
not statistically differ in both groups. However, hypogranulated and
vacuolized neutrophils were significantly associated with survival.
doi:10.1016/j.immbio.2011.11.026
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Thrombin generation, flow cytometry and electron
microscopy is a useful combination to study
tissue-factor bearing microparticles in thrombosis
associated with breast cancer
F. Mullier a,b, E. Varina, D. Gheldofa, J. Hardij a, S. Robert a,
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Hemostasis Center (NTHC), University of Namur, Namur, Belgium
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Hemostasis Center (NTHC), UCL Mont-Godinne, Yvoir, Belgium
c Hematology, NARILIS, Namur Thrombosis and Hemostasis Center
(NTHC), UCL Mont-Godinne, Yvoir, Belgium
d Department of Biology, NARILIS, University of Namur, Namur,
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Introduction.— Patients with cancer have a 7- to 10-fold overall
increased risk of developing venous thromboembolism (VTE). This
risk has been notably associated with circulation of active tissue
actor (TF) bearing microparticles (TF-MPs) shedding from tumors
cells.
Aims.— The primary objectives of this study were to characterize
structure, size and PCA of tumor-cell derived MPs released by breast
cancer cells MDA-MB-231 (MDA) using thrombin generation assay
(TGA), flow cytometry (FCM) and transmission electron microscopy
(TEM).
Methods.— Serial dilutions of cell suspension (MDA) were incubated
for 45min at 37 ◦C with/without stirring condition. Samples were
then centrifuged to remove cells according to three different pro-
tocols and the supernatants (Sup), containing MPs, were used for
EM, FCM and TGA. Alternatively, MP fractions were filtered through
0.1, 0.22, 0.45 or 0.65m membranes and subjected to activity
assays.
Results.—
— At the highest concentration (600,000 MDA cells/mL), neither the
stirring nor the type of centrifugation significantly influenced TGA
results.
— MDA and MDA Sup significantly increased the active thrombin in
comparison to Normal Pool Plasma (NPP) alone. MPs fraction deri-
ved from 500 MDA cells/ml is sufficient to significantly increase the
thrombin generation of NPP. The highly significant difference bet-
ween MDA and its Sup was due to a loss of MPs by centrifugation as
shown by FCM.
— Both PL and TF contributed to PCA of MPs, but at different stages
of the coagulation cascade. Active TF is mainly present on the MPs.
— EM showed that MPs derived from MDA-MB-231 are comprised bet-
ween 30 and 200 nm and that the vast majority were under 100 nm.
Such results were in agreement with FCM and TGA.
Conclusions.— TGA, FCM and TEM are very interesting methods that
should be combined to adequately determine the phenotype of
tumor-cell derived MPs whatever their size. More sensitive tech-
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ackground.— Microparticles (MP) have high potential as diagnos-
ic biomarkers. Standardization of their analysis by flow cytometry
s limited by size-related issues. Submicron beads (Megamix [Mgx])
ere proposed to help qualifying instruments and measure a repro-
ucible part of the largest MP.
bjectives.— Based on this initial approach, the aim of this study
as to develop a formula to determine the ability of a flow cyto-
eter (FCMr) to study the ‘‘large MP’’ subset, to monitor the
nstrument, to study possible optimization via technical service
r optics modification and to compare instrument performance.
esolution in scatter parameters was compared on 14 FCMrs of dif-
erent types and brands (at least 1 of each), using a separation
ndex (SI) based on the FSC or SSC peaks of Mgx and calculated
s follows: SI = (median 0.9m—median 0.5m)/(S.D. 0.9m+S.D.
.5m). The relative positions of platelet MP and Mgx were also
ompared.
esult.— As a result, BD FACSCantoII, AriaI or LSRII showed signifi-
ant inter-instrument variability on FSC with highly variable SI (< 3
o 23) but more homogeneous and higher SI based on SSC (4.5 to
5), suggesting a preferential use of SSC for sizing MP. BC FC500 and
allios showed rather homogeneous FSC resolution with SI from 5 to
5.5 and 25 to 35, respectively. AccuriC6 showed FSC SI from 8.5 to
1; Attune, FACSAriaII, LSR-Fortessa, BD Influx, Partec Cy-Flow sho-
ed encouraging resolution (SI > = 10); Levy-Jennings charts of FSC
I allowed raising the need for maintenance; optics optimization
rials led to improved FSC resolution on LSR-Fortessa and Apogee
50. Thus, FS/FSC resolution (SI value with Mgx) is a useful Q.C.
arameter for MP analysis.
onclusion.— Comparing multiple FCMrs’ behavior may lead us to
ropose some modifications to the current ISTH MP protocol spe-
ifically for BD instruments, with emphasis on the use of SSC. This
ay require new standardization tools since relative positions of
iological MP as compared to beads are different in SSC and FSC.
oi:10.1016/j.immbio.2011.11.028
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ntroduction.— Delta storage pool disease (dSPD) is probably the
ost frequent platelet disorder but is still underdiagnosed. Several
ethods exist to document dSPD among which flow cytometry (FCM)
sing mepacrine (fluorescent acridine derivative, which rapidly
inds with high affinity and specificity to adenine nucleotides in
latelet dense granules). However, neither standardization nor
nternational recommendations exist.
ethods.—
In center 1, to assess a defined mepacrine FCM protocol (BD
ACSCalibur) when dSPD is suspected, 99 patients with bleeding
ymptoms were studied. Comparison with BC Navios (centre 1) and
D FACSCantoII (centre 3) were performed;
Preanalytical, analytical and postanalytical variables were asses-
ed on CantoII (centre 2);
After definition of a consensus revised protocol, normal values
n = 20) of the two protocols were compared on the same samples
rom healthy subjects. Within assay variation (n = 10) was establi-
hed;
The new protocol was applied to 14 samples from 12 patients
uspected of dSPD and compared with the former (n = 3);
Two samples from healthy subjects were run in two centers with
3-hour time delay.
esults.—
We noted that 37 patients showed a pattern in LTA, ATP
ecretion or mepacrine testing, suggestive of dSPD. Analysis of
epacrine capture and release, TRAP-induced CD63 platelet mem-
rane expression may allow a mechanistic classification of storage
ool defects;
The major changes in the consensus revised protocol are: whole
lood instead of PRP, optimization of mepacrine concentration and
nclusion of red blood cells as an internal control;
Within assay variation for mepacrine capture and release were
.0 and 6.6%, respectively;
The same laboratory conclusion was obtained for the three
amples suspected of dSPD run with both protocols in one centre
nd for the two same samples run in both centres.
onclusions.— We propose a validated consensus rapid protocol for




valuation du reactif lamotrigine QMS® automatisé
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ntroduction.— Disponible depuis 2002 (AMM) en France, la
amotrigine (Lamictal®) est un antiépileptique ayant des proprié-
és thymorégulatrices. Habituellement dosée par CLHP, l’étude
orte ici sur l’évaluation du réactif QMS® par immunotur-
idimétrie sur l’automate CDx90® (Microgenics ThermoFisher
cientific).
éthodes.— Le principe de la technique est un phénomène de
ompétition, en présence de lamotrigine, du développement d’une
urbidité avec une détection à 700 nm ; le calibrage est effectué en
points (de 0 à 40mg/L). Les performances analytiques et la stabi-
ité du réactif ont été évaluées à l’aide des solutions de contrôle
t de calibrage du fournisseur. Les échantillons sériques de quatre
atients ont été dosés et comparés avec une technique de CLHP
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ésultats.— Les limites de détection et de quantification sont res-
ectivement de 0,48 et 0,66mg/L (n = 15). La répétabilité (n = 15)
ur deux niveaux de contrôle (2 et 8,5mg/L) présente des coef-
cients de variation (CV) inférieurs à 4 %. Les biais moyens
ont respectivement de 0,5 % et de —1%. Le CV de reproduc-
ibilité (n = 15) est inférieur à 5 % à 2mg/L et égal à 18,6 %
our 8,5mg/L. Il n’existe pas de contamination inter-échantillons
ntre le calibrant à 2,5mg/L et celui à 20mg/L. On observe
ne relation linéaire significative entre la concentration en lamo-
rigine et le temps après calibrage pour le contrôle à 2mg/L
R2 = 0,4720) et celui à 8,5mg/L (R2 = 0,9158) (p < 0,05). Le biais
tteint —10% au bout de 12 jours pour le contrôle à 2mg/L (sept
ours pour le celui à 8,5mg/L). Par rapport à la technique de
LHP, les résultats sont les suivants : < 0,66mg/L (< 0,5), 1,52mg/L
+26,7 %), 2,48mg/L (3,3 %) et 16,97mg/L (—3,6 %) (dilution au
ixième).
onclusion.— Le réactif QMS Lamotrigine sur CDx90 permet un
osage rapide et aisé de ce médicament pour des concentrations
ériques proches de 2mg/L (zone thérapeutique en épilepsie). La
tabilité du réactif impose cependant un calibrage tous les 12 jours.
oi:10.1016/j.immbio.2011.11.030
0
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ntroduction.— Le thiopental est un barbiturique utilisé en réani-
ation pour induire l’anesthésie et/ou un coma thérapeutique.
on dosage sanguin ou celui des barbituriques totaux est un
lément pouvant contribuer au diagnostic de mort cérébrale
vant un éventuel prélèvement d’organes. Nous avons évalué une
echnique d’immunoanalyse automatisée pour le dosage en rou-
ine des barbituriques totaux chez les patients traités par du
hiopental.
atériels et méthodes.— Les barbituriques ont été mesurés sur
n automate CDx90® (Microgenics Thermo Fischer Scientifics) avec
n réactif CEDIA® du fournisseur. La calibration est réalisée en
points avec du secobarbital (200 à 3000 ng/mL). La répétabilité
t reproductibilité ont été évaluées à partir des contrôles Microge-
ics (C1 : 225 ng/mL ; C2 : 375 ng/mL). La limite de quantification
été déterminée par dilution dans du plasma du point de cali-
ration 200 ng/mL. Pour le thiopental, le facteur de récupération
t le domaine de mesure ont été établis par surcharge de plasma
partir d’une solution mère de Pentothal® (Hospira France). Les
oncentrations de barbituriques ont été mesurée dans le plasma de
= 19 patients de réanimation traités (n = 4) ou non (n = 15) par du
hiopental. Les statistiques ont été effectuées à l’aide du logiciel
ethval®.
ésultats.— Les CV (%) de la répétabilité et de la reproductibilité
ont pour C1 compris entre 2,4 % et 5,2 % et pour C2 entre 2,8 % et
,9 %. La justesse est de 84% et de 92% respectivement pour C1 et
2. La stabilité de la calibration est de trois semaines, le réac-
if étant stocké à +4 ◦C. La limite de quantification observée est
e 100 ng/mL ; la plage analytique s’étend de 125 à 2500 ng/mL de
lasma. Le facteur de récupération du thiopental est de 8,8 % pour
ne concentration allant de 1,4 à 28,4mg/L (corrélation Passing
ablok, r = 0,965 ; n = 6). Les échantillons des patients non traités
ar thiopental ont tous été retrouvés négatifs. Les patients traités
ar du thiopental ont des taux détectables de barbituriques jusqu’à
ept jours après l’arrêt du traitement. La stabilité des échantillons
